ATE228823T1 - Pharmazeutische aerosolformulierung - Google Patents

Pharmazeutische aerosolformulierung

Info

Publication number
ATE228823T1
ATE228823T1 AT99916921T AT99916921T ATE228823T1 AT E228823 T1 ATE228823 T1 AT E228823T1 AT 99916921 T AT99916921 T AT 99916921T AT 99916921 T AT99916921 T AT 99916921T AT E228823 T1 ATE228823 T1 AT E228823T1
Authority
AT
Austria
Prior art keywords
aerosol formulation
pharmaceutical aerosol
pharmaceutical
formulation
aerosol
Prior art date
Application number
AT99916921T
Other languages
English (en)
Inventor
P Cavaillon
N Llorca
O Louis
P Rosier
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE228823T1 publication Critical patent/ATE228823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99916921T 1998-04-18 1999-04-15 Pharmazeutische aerosolformulierung ATE228823T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation
PCT/EP1999/002535 WO1999053901A1 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
ATE228823T1 true ATE228823T1 (de) 2002-12-15

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916921T ATE228823T1 (de) 1998-04-18 1999-04-15 Pharmazeutische aerosolformulierung

Country Status (30)

Country Link
US (1) US7521042B2 (de)
EP (1) EP1073417B1 (de)
JP (1) JP2002512183A (de)
KR (1) KR20010042816A (de)
CN (1) CN1145478C (de)
AP (1) AP2000001961A0 (de)
AR (1) AR018183A1 (de)
AT (1) ATE228823T1 (de)
AU (1) AU755066B2 (de)
BR (1) BR9909736A (de)
CA (1) CA2328882A1 (de)
CO (1) CO5021210A1 (de)
DE (1) DE69904312T2 (de)
DK (1) DK1073417T3 (de)
EA (1) EA200000956A1 (de)
EE (1) EE200000608A (de)
ES (1) ES2189410T3 (de)
HR (1) HRP20000689A2 (de)
HU (1) HUP0101608A2 (de)
ID (1) ID27887A (de)
IL (1) IL139087A0 (de)
IS (1) IS5665A (de)
MA (1) MA26621A1 (de)
NO (1) NO20005218L (de)
NZ (1) NZ507619A (de)
PE (1) PE20000433A1 (de)
PL (1) PL343491A1 (de)
PT (1) PT1073417E (de)
TR (1) TR200100144T2 (de)
WO (1) WO1999053901A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
ES2587135T3 (es) 2000-11-30 2016-10-20 Vectura Limited Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
JP4380988B2 (ja) † 2000-11-30 2009-12-09 ヴェクトゥラ リミテッド 医薬組成物に用いられる粒子の製造方法
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
AU2003297320B8 (en) * 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1628641A2 (de) * 2003-05-19 2006-03-01 Baxter International Inc. Feste partikel, die ein antikonvulsivum oder ein immunsuppressivum enthalten und die mit einer oder mehreren oberflächen-modifizierenden substanzen beschichtet sind
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1833822A2 (de) 2004-08-16 2007-09-19 Theravance, Inc. Verbindungen mit beta2 adrenerg-rezeptor agonistischer und muscarin-rezeptor antagonistischer aktivität
JP5156397B2 (ja) * 2005-02-10 2013-03-06 グラクソ グループ リミテッド 予備分級技術を用いて乳糖を製造する方法及びその乳糖から形成させた医薬製剤
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
PL3578169T3 (pl) 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
HUE026414T2 (hu) 2009-07-15 2016-05-30 Theravance Biopharma R&D Ip Llc Bifenil-vegyület kristályos szabad-bázis formája
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
JP5572706B2 (ja) 2010-06-08 2014-08-13 学校法人神戸学院 コーティング粒子及びコーティング粒子の製造方法
CN105078973B (zh) 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
KR20200015828A (ko) * 2012-02-28 2020-02-12 아이슈티카 홀딩스 인코포레이티드. 흡입용 약제학적 조성물
US9700558B2 (en) 2013-03-15 2017-07-11 Verona Pharma Plc Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
SI3142701T1 (en) 2014-05-12 2018-08-31 Verona Pharma Plc NEW TREATMENT
EP3872069A1 (de) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
CN119868317A (zh) 2018-02-08 2025-04-25 南加州大学 穿透血脑屏障的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
WO1988001165A1 (en) * 1986-08-11 1988-02-25 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DK0834314T3 (da) * 1995-06-12 2003-02-24 Ono Pharmaceutical Co Granuler der indeholder pranlukast, fremgangsmåde til fremstilling af granulerne, og fremgangsmåde til reduktion af pranlukasts klæbeevne
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
JP2001507701A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物

Also Published As

Publication number Publication date
EP1073417B1 (de) 2002-12-04
HUP0101608A2 (hu) 2002-03-28
CN1145478C (zh) 2004-04-14
MA26621A1 (fr) 2004-12-20
NZ507619A (en) 2003-05-30
CA2328882A1 (en) 1999-10-28
US20030157032A1 (en) 2003-08-21
WO1999053901A1 (en) 1999-10-28
US7521042B2 (en) 2009-04-21
NO20005218L (no) 2000-11-10
CN1305369A (zh) 2001-07-25
JP2002512183A (ja) 2002-04-23
IS5665A (is) 2000-10-13
DK1073417T3 (da) 2003-03-24
DE69904312D1 (de) 2003-01-16
PT1073417E (pt) 2003-04-30
KR20010042816A (ko) 2001-05-25
EA200000956A1 (ru) 2001-04-23
DE69904312T2 (de) 2003-10-16
NO20005218D0 (no) 2000-10-17
PL343491A1 (en) 2001-08-27
IL139087A0 (en) 2001-11-25
EE200000608A (et) 2001-08-15
AP2000001961A0 (en) 2000-12-31
EP1073417A1 (de) 2001-02-07
AU3523199A (en) 1999-11-08
PE20000433A1 (es) 2000-05-26
ID27887A (id) 2001-05-03
AR018183A1 (es) 2001-10-31
HRP20000689A2 (en) 2001-02-28
TR200100144T2 (tr) 2001-06-21
ES2189410T3 (es) 2003-07-01
AU755066B2 (en) 2002-12-05
BR9909736A (pt) 2000-12-19
CO5021210A1 (es) 2001-03-27

Similar Documents

Publication Publication Date Title
DE69904312D1 (de) Pharmazeutische aerosolformulierung
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DE69525148D1 (de) Pharmazeutische formulierung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO992339L (no) Farmasöytiske formuleringer
NO20012915D0 (no) Ny farmasöytisk formulering
DE69530325D1 (de) Aerosol-arzneiformulierungen
ATE432707T1 (de) Pharmazeutische zubereitung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID30032A (id) Formulasi farmasi
DE69830154D1 (de) Pharmazeutische zusammensetzungen
AR025867A1 (es) Formulacion portasdora farmaceutica
EP1124557A4 (de) Pharmazeutische zusammensetzung
DE19681529D2 (de) Pharmazeutische Darreichungsform
SE9803952D0 (sv) Pharmaceutical formulation
ATA77096A (de) Pharmazeutische präparation
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
GB9814709D0 (en) Pharmaceutical aerosol formulation
GB9808152D0 (en) Pharmaceutical aerosol formulation
SI1073417T1 (en) Pharmaceutical aerosol formulation
SE9600141D0 (sv) Pharmaceutical formulation
EP1095026A4 (de) Pharmazeutische mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073417

Country of ref document: EP

REN Ceased due to non-payment of the annual fee